Poor glycemic control increases the risk of long-term complications, while overtreatment exposes patients to hypoglycemia. In this study, we examined the rates and correlates of potential overtreatment and undertreatment among adults (≥18 years) with diabetes using OptumLabs® Data Warehouse, an administrative claims dataset of commercial and Medicare Advantage enrollees across the U.S. Patient comorbidities were ascertained in 2014. Demographics, HbA1c, glucose-lowering medications, and attributed provider (internal medicine [IM], family medicine [FM], endocrinology) were ascertained in 2015. Patients were classified as potentially over- or undertreated based on their HbA1c, treatment regimen, and clinical complexity.

The study cohort was comprised of 215,429 adults with diabetes; mean age 65.0 years, 59.4% white, 4.2% with type 1 diabetes, 23.1% ≥75 years, and 12.1% clinically complex. Overall, 21.3% were undertreated (22.7% low complexity, 10.9% high complexity) and 7.7% overtreated (5.4% low complexity, 23.8% high complexity).

Younger age, male sex, black/Hispanic race/ethnicity, type 1 diabetes, FM management, and low clinical complexity were associated with glycemic undertreatment (Table). Younger age, male sex, white/Asian race/ethnicity, type 1 diabetes, endocrine management, and high clinical complexity were associated with glycemic overtreatment.
Disclosure

R.G. McCoy: None. K.J. Lipska: Consultant; Self; Health Services Advisory Group (HSAG). Research Support; Self; National Institute on Aging. Other Relationship; Self; Centers for Medicare and Medicaid Services. H. Van Houten: None. N. Shah: None.

Funding

American Association of Retired Persons; OptumLabs; National Institute of Diabetes and Digestive and Kidney Diseases (K23DK114497)

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.